Mirum Pharmaceuticals Inc
NASDAQ:MIRM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.57
46.26
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MIRM stock under the Base Case scenario is 44.81 USD. Compared to the current market price of 44.46 USD, Mirum Pharmaceuticals Inc is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mirum Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MIRM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Mirum Pharmaceuticals Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mirum Pharmaceuticals Inc
Balance Sheet Decomposition
Mirum Pharmaceuticals Inc
Current Assets | 386.6m |
Cash & Short-Term Investments | 284.4m |
Receivables | 68.5m |
Other Current Assets | 33.7m |
Non-Current Assets | 281.3m |
Long-Term Investments | 9.3m |
PP&E | 10.3m |
Intangibles | 255.8m |
Other Non-Current Assets | 5.8m |
Current Liabilities | 115.8m |
Accounts Payable | 9.5m |
Accrued Liabilities | 106.2m |
Non-Current Liabilities | 320.1m |
Long-Term Debt | 307.7m |
Other Non-Current Liabilities | 12.5m |
Earnings Waterfall
Mirum Pharmaceuticals Inc
Revenue
|
307m
USD
|
Cost of Revenue
|
-83.9m
USD
|
Gross Profit
|
223.1m
USD
|
Operating Expenses
|
-319.1m
USD
|
Operating Income
|
-96m
USD
|
Other Expenses
|
-3.8m
USD
|
Net Income
|
-99.8m
USD
|
Free Cash Flow Analysis
Mirum Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
MIRM Profitability Score
Profitability Due Diligence
Mirum Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Mirum Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
MIRM Solvency Score
Solvency Due Diligence
Mirum Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Mirum Pharmaceuticals Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MIRM Price Targets Summary
Mirum Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for MIRM is 63.61 USD with a low forecast of 50.5 USD and a high forecast of 74.55 USD.
Dividends
Current shareholder yield for MIRM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MIRM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 137 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The firm's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
Contact
IPO
Employees
Officers
The intrinsic value of one MIRM stock under the Base Case scenario is 44.81 USD.
Compared to the current market price of 44.46 USD, Mirum Pharmaceuticals Inc is Undervalued by 1%.